Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Short-term effect of the New Nordic Renal Diet on phosphorus homoeostasis in chronic kidney disease Stages 3 and 4

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Hypertensive nephropathy is associated with an increased risk of myeloma, skin, and renal cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. FGF23 in hemodialysis patients is associated with left ventricular hypertrophy and reduced ejection fraction

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Quantification of cancer risk in glomerulonephritis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Autosomal dominant polycystisk nyresygdom

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Edwin M Spithoven
  • Anneke Kramer
  • Esther Meijer
  • Bjarne Orskov
  • Christoph Wanner
  • Jose M Abad
  • Nuria Aresté
  • Ramón Alonso de la Torre
  • Fergus Caskey
  • Cécile Couchoud
  • Patrik Finne
  • James Heaf
  • Andries Hoitsma
  • Johan de Meester
  • Julio Pascual
  • Maurizio Postorino
  • Pietro Ravani
  • Oscar Zurriaga
  • Kitty J Jager
  • Ron T Gansevoort
  • ERA-EDTA Registry
Vis graf over relationer

BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is the fourth most common renal disease requiring renal replacement therapy (RRT). Still, there are few epidemiological data on the prevalence of, and survival on RRT for ADPKD.

METHODS: This study used data from the ERA-EDTA Registry on RRT prevalence and survival on RRT in 12 European countries with 208 million inhabitants. We studied four 5-year periods (1991-2010). Survival analysis was performed by the Kaplan-Meier method and by Cox proportional hazards regression.

RESULTS: From the first to the last study period, the prevalence of RRT for ADPKD increased from 56.8 to 91.1 per million population (pmp). The percentage of prevalent RRT patients with ADPKD remained fairly stable at 9.8%. Two-year survival of ADPKD patients on RRT (adjusted for age, sex and country) increased significantly from 89.0 to 92.8%, and was higher than for non-ADPKD subjects. Improved survival was noted for all RRT modalities: haemodialysis [adjusted hazard ratio for mortality during the last versus first time period 0.75 (95% confidence interval 0.61-0.91), peritoneal dialysis 0.55 (0.38-0.80) and transplantation 0.52 (0.32-0.74)]. Cardiovascular mortality as a proportion of total mortality on RRT decreased more in ADPKD patients (from 53 to 29%), than in non-ADPKD patients (from 44 to 35%). Of note, the incidence rate of RRT for ADPKD remained relatively stable at 7.6 versus 8.3 pmp from the first to the last study period, which will be discussed in detail in a separate study.

CONCLUSIONS: In ADPKD patients on RRT, survival has improved markedly, especially due to a decrease in cardiovascular mortality. This has led to a considerable increase in the number of ADPKD patients being treated with RRT.

OriginalsprogEngelsk
TidsskriftNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Vol/bind29 Suppl 4
Sider (fra-til)iv15-25
ISSN0931-0509
DOI
StatusUdgivet - sep. 2014

ID: 44856434